4. 不起訴處分，司法還醫華創辦人公道
Instead of prosecution and punishment, justice will return justice to the founder of CytoAurora

醫華生技聲明稿：

對於2019年所發生的「癌症檢測晶片遭爆料偷自美國名校」一事，經過兩年時間司法調查，終獲不起訴處分。本公司說明如下：

1.對於當時媒體報導，美國UCLA曾教授於媒體前表示，醫華生技涉嫌抄襲技術等情事，明顯與事實嚴重背離，且對醫華生技形象造成莫大影響。

2.經過新竹地檢署近兩年調查，發現事實與曾教授提告商業詐欺內容不符，是以，於今年正式以不起訴處分定讞。

3.醫華生技成立近六年，所有專利與智慧財產權皆屬自有，不容惡意商業抹黑，為維護名譽，醫華生技亦將對曾教授保留法律追訴權。

此次地檢署做出不起訴處分一事，醫華生技創辦人兼CEO黃忠諤博士表示這是遲來的正義，感謝司法還他一個公道。秉持企業對守護全民的責任，未來醫華生技將賡續戮力於癌症檢測平台之開發，利用台灣半導體之優勢，百分之百台灣研發製造，結合特殊晶片與AI技術，提供尖端精準之醫療檢測，共同為促進台灣精準醫療發展而努力。

CytoAurora Biotech’s statement:

Regarding the 2019 incident in which "cancer detection chips were revealed to have been stolen from prestigious American schools," after two years of judicial investigation, the case was finally dismissed without prosecution. The company explains as follows:

1. Regarding media reports at the time, Professor Zeng from UCLA in the United States stated in front of the media that CytoAurora Biotech was suspected of plagiarizing technology, which was obviously a serious deviation from the facts and had a great impact on the image of CytoAurora Biotech.

2. After nearly two years of investigation by the Hsinchu District Prosecutor’s Office, it was found that the facts were inconsistent with the contents of Professor Zeng’s commercial fraud complaint. Therefore, CytoAurora Biotech was officially sentenced this year to non-prosecution.

3. CytoAurora Biotechnology has been established for nearly six years. All patents and intellectual property rights are its own and cannot be smeared by malicious business. In order to protect its reputation, CytoAurora Biotechnology will also retain the right of legal recourse against Professor Zeng.

This time the District Attorney's Office decided not to prosecute. Dr. Huang Chung-Er, founder and CEO of CytoAurora Biotechnology, said that this was delayed justice and he thanked the judiciary for giving him justice. Upholding the company's responsibility to protect the people, CytoAurora Biotech will continue to work hard on the development of cancer detection platforms in the future, leveraging the advantages of Taiwan's semiconductors, 100% R&D and manufacturing in Taiwan, and combining special chips and AI technology to provide cutting-edge and accurate medical detection. Work together to promote the development of precision medicine in Taiwan.